if this works???, page-4

History shows in this type of bio tech that a major eg. Pfizer, Roche, Kline keep a very close watch on the trials as they progress with an eye to becoming involved in the manufacture and distribution of the vaccine. From a shareholders point of view the rewards come a lot earlier than suggested in above posts as one of these majors will take a strong position in the company around the 10% mark months before trials are completed. They work on a royalty deal with the bio-tech and invest in the hundreds of millions of dollars. The share price rises significantly on these licensing deals and in the case of PRR this could occur within a few short months. $25 looks like a very long shot but nothing is impossible in this multi billion dollar industry. Today's price will look silly in a very shoart time.